RecruitingNCT06883240

An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment

A Multicenter Non-Interventional Study Evaluating Bleeds and Health-Related Quality Of Life in Patients With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment


Sponsor

Hoffmann-La Roche

Enrollment

40 participants

Start Date

Apr 29, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

This non-interventional study (NIS) is designed to collect information on the effectiveness and safety of treatment received in routine clinical care, as well as measure the health-related quality of life (HRQoL) of participants with Type 3 von Willebrand disease (VWD) receiving prophylactic therapy per local standard of care (SOC) over an observation period of at least 24 weeks.


Eligibility

Min Age: 2 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Activated Prothrombin Complex Concentrate, a drug called Factor VIII Concentrates, and others for people with von willebrand disease, type 3. The study is currently recruiting participants at 27 locations. People eligible for this study include aged 2 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVon Willebrand Factor Concentrates

Used according to local labeling or local treatment guidelines.

DRUGVon Willebrand Factor Concentrates and Factor VIII Concentrates

Used according to local labeling or local treatment guidelines.

DRUGFactor VIII Concentrates

Used according to local labeling or local treatment guidelines.

DRUGRecombinant Activated Factor VII

Used according to local labeling or local treatment guidelines.

DRUGActivated Prothrombin Complex Concentrate

Used according to local labeling or local treatment guidelines.


Locations(27)

UC Davis

Sacramento, California, United States

University of Florida

Gainesville, Florida, United States

University of Minnesota Medical Center

Minneapolis, Minnesota, United States

Washington University School of Medicine

St Louis, Missouri, United States

UZ Leuven Gasthuisberg

Leuven, Belgium

The Hospital for Sick Children

Toronto, Ontario, Canada

McGill University Health Center

Montreal, Quebec, Canada

IPS SURA Industriales Medellín

Medellín, Colombia

Hopital Claude Huriez - CHU Lille

Lille, France

Groupe Hospitalier Necker Enfants Malades

Paris, France

Universitätsklinikum Bonn

Bonn, Germany

Gerinnungszentrum Rhein-Ruhr;Gerinnungsambulanz

Duisburg, Germany

Hämophiliezentrum Med. Klinik III/Institut für Transfusionsmedizin

Frankfurt/M., Germany

Universita' Degli Studi La Sapienza-Ist.Di Ematologia

Rome, Lazio, Italy

IRCCS Ca' Granda Ospedale Maggiore Policlinico

Milan, Lombardy, Italy

AOU Careggi

Florence, Tuscany, Italy

Kurume University Hospital

Fukuoka, Japan

Tokyo Medical University Hospital

Tokyo, Japan

Erasmus MC

Rotterdam, Netherlands

Instytut Hematologii i Transfuzjologii

Warsaw, Poland

Charlotte Maxeke Johannesburg Academic Hospital

Johannesburg, South Africa

Hospital Universitario la Paz

Madrid, Spain

Hospital Universtiario Virgen del Rocio

Seville, Spain

Sahlgrenska Universitetssjukhuset

Gothenburg, Sweden

St Thomas' Hospital

London, United Kingdom

Great Ormond Street Hospital

London, United Kingdom

Manchester Royal Infirmary

Manchester, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06883240


Related Trials